Nasal administration of morphine-6-glucuronide in sheep - A pharmacokinetic study

Biopharmaceutics and Drug Disposition

Volumn 17, Issue 8, 1996, Pages 717-724

  Illum, L ^a,b   Davis, S S ^a,b   Pawula, M ^b   Fisher, A N ^a   Barrett, D A ^b   Farraj, N F ^a   Shaw, P N ^b  

^a Albert Einstein Centre   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

chitosan; morphine 6 glucuronide; nasal; pharmacokinetics; sheep model

Indexed keywords

MORPHINE; MORPHINE 6 GLUCURONIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; FEMALE; INTRANASAL DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; SHEEP; SUBCUTANEOUS DRUG ADMINISTRATION;

ABSORPTION; ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHITIN; CHITOSAN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MORPHINE DERIVATIVES; SHEEP;

EID: 0029840181     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199611)17:8<717::AID-BDD985>3.0.CO;2-I     Document Type: Article

References (25)

1. R. Osborne, S. P. Joel, D. Trew and M. L. Slevin, Analgesic activity of morphine-6-glucuronide. Lancet, i, 828 (1988).
2. R. J. Osborne, S. Joel, D. Trew and M. Slevin, Morphine and metabolic behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin. Pharmacol. Ther., 47, 12-19 (1990).
3. J. Sawe, Morphine and its 3- and 6-glucuronides in plasma and urine during chronic oral administration in cancer patients. In Advances in Pain Research and Therapy, K. M. Foley and C. E. Inturrisi (Eds), Raven, New York, 1986, pp. 45-55.
4. T. Matsuzawa, Y. Wada, M. Shimoyama, K. Nakajima, T. Seki, K. Sugibayashi and M. Shimoyama, The effect of different routes of administration on the metabolism of morphine: the disposition of morphine and its metabolites after topical application. Biopharm. Drug Disposit., 15, 665-678 (1994).
5. R. Osborne, P. Thompson, S. Joel, D. Trew, N. Patel and M. Slevin, The analgesic activity of morphine-6-glucuronide. Br. J. Clin. Pharmacol., 34, 130-138 (1992).
6. O. Kamata, S. Watanabe, S. Ishii, S. Veki, K. Oguri, S. Ida, H. Yoshimura and H. Tsukamoto, Analgesic effect of morphine glucuronides, Proceedings of the 89th Meeting of the Pharmacology Society of Japan, 1969, p. 443.
7. K. Shimomura, O. Kamata, S. Veki, S. Ida, K. Oguri, H. Yoshimura and H. Tsukamoto, Analgesic effect of morphine glucuronides. Tohuku J. Exp. Med., 105, 45-52 (1971).
8. G. W. Pasternak, R. J. Bodnar, J. A. Clark and C. E. Inturrisi, Morphine-6-glucuronide, a potent mu agonist. Life Sci., 41, 2845-2849 (1987).
9. M. H. Hanna, S. J. Peat, M. Woodham, A. Knibb and C. Fung, Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br. J. Anaesth., 64, 547-550 (1990).
10. R. J. Osborne, S. P. Joel, D. Trew and M. Slevin, The pharmacokinetics of morphine and morphine glucuronides in normal volunteers after four routes of administration. Br. J. Cancer, 23, 227-228 (1986).
11. M. H. Hanna, S. J. Peat, A. A. Knibb and C. Fung, Disposition of morphine-6-glucuronide and morphine in healthy volunteers. Br. J. Anaesth., 66, 103-107 (1991).
12. A. Avdeef, D. A. Barrett, P. N. Shaw, R. D. Knaggs and S. S. Davis, Octanol-, chloroform-, and PGDP-water partitioning of morphine-6-glucuronide and other related opioids. J. Med. Chem. submitted.
13. L. Illum, N. F. Farraj and S. S. Davis, Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res., 11, 1186-1189 (1994).
14. L. Illum, Animal models for nasal delivery. J. Drug Targeting, in press.
15. N. F. Farraj, B. R. Johansen, S. S. Davis and L. Illum, Nasal administration of insulin using bioadhesive microspheres as a delivery system. J. Control. Rel., 13, 253-261 (1990).
16. M. Pawula, D. A. Barrett and P. N. Shaw, An improved extraction method for the HPLC determination of morphine and its metabolites in plasma. J. Pharm. Biomed. Anal., 11, 401-406 (1993).
17. P. A. Sloan, L. E. Mather, C. F. McLean, A. J. Rutten, R. L. Nation, R. W. Milne, W. B. Runciman and A. A. Somogyi, Physiological disposition of i.v. morphine in sheep. Br. J. Anaesth., 67, 378-386 (1991).
18. R. W. Milne, P. A. Sloan, C. F. McLean, L. E. Mather, R. L. Nation, W. B. Runciman, A. J. Rutten and A. A. Somogyi, Disposition of morphine and its 3- and 6-glucuronide metabolites during morphine infusion in the sheep. Drug Metab. Disposit., 21, 1151-1156 (1993).
19. P. Artursson, T. Lindmark, S. S. Davis and L. Illum, The effect of chitosan on the permeability of monolayers of intestinal epithelial cells (CaCo-2). Pharm. Res., 11, 1358-1361 (1994).
20. T. J. Aspden, J. Adler, S. S. Davis, Ø. Skaugrud and L. Illum, Chitosan as a nasal delivery system: evaluation of the effect of chitosan on mucociliary clearance rate in the frog palate model. Int. J. Pharm., in press.
21. N. C. T. Wilton, J. Leigh, D. Rosen and U. Pandit, Intranasal midazolam premedication in pre-school chilren. Anesth. Analg., 67, S260 (1988).
22. J. A. Aldrete, J. C. Roman-de-Jesus, L. J. Russell and O. DCruz, Intranasal ketamine as induction adjunct in children: preliminary report. Anesthesiology, 67, A514 (1987).
23. M. Vercauteren, E. Boeckx, G. Hanegreefs, H. Noorduin and G. Vanden Bussche, Intranasal sufentanil for preoperative sedation. Anaesthesia, 43, 270-273 (1988).
24. F. E. Ralley, Intranasal opiates: old route for new drugs. Can. J. Anaesth., 36, 491-493.
25. M. H. Hanna, S. J. Peat, A. A. Knibb and C. Fung, Disposition of morphine-6 glucuronide and morphine in healthy volunteers. Br. J. Anaesth., 66, 103-107 (1991).